Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Oramed'PlatformTech In Oral Delivery Of Proteins Gets Patent In Israel,Australia

Oramed Pharmaceuticals Inc. (ORMP: Quote), a developer of oral drug delivery systems, announced Thursday that it has received Notices of Allowance from the Israel and Australian Patent Offices.

The patent entitled, "Methods and Compositions for Oral Administrations of Proteins" covers a core concept of the company's technology for the oral delivery of drugs and vaccines currently delivered via injection.

The company stated that the allowance in Israel marks the second from the Israel Patent Office in the past 30 days. Additionally, this is Oramed's second Australian patent allowance, following the grant of a different patent in May 2012.

The company noted that the patent has also been approved in Japan, China, Russia, and New Zealand.

Click here to receive FREE breaking news email alerts for Oramed Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Russia has agreed to resume gas supplies to Ukraine under a $4.6 billion dollar winter package, which will also secure gas for the European Union as the cold season approaches. The European Union has been mediating discussions to help find a sustainable solution to the dispute between Russia and Ukraine over gas pricing, supply and payment dues. After seven rounds of negotiations in recent months The Bank of Japan expanded its massive quantitative and qualitative easing unexpectedly as policymakers assessed it necessary to achieve the 2 percent inflation target even after a sales tax hike in April. In a 5-4 vote, the Policy Board led by Governor Haruhiko Kuroda decided to raise the monetary base at an annual pace of about JPY 80 trillion. LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.